No 04 2024

The President and CEO of Camurus, Fredrik Tiberg, has been named the winner of The Arthur D. Little Nordic Life Science Award.

Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product. 

The gala, organized by the Women in Business network, highlights female role models and works towards a more gender-equal corporate sector.

The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.

The US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.

Paxman has announced a recommended offer to the shareholders of Dignitana to transfer all shares issued by Dignitana to Paxman, against consideration in the form of a total of 2,476,207 newly issued shares in Paxman.

Ted Fjällman (TF), CEO of the Swedish listed investment company Flerie, and Tim Opler (TO), Managing Director of the global healthcare group at investment firm Stifel, both work with life science investments in Europe, the USA and globally. They share, in a conversation format, their thoughts about the financial landscape and the Nordic life science ecosystem.